Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Hemoperfusion as an Adjuvant Therapy in Maintenance Hemodialysis Patients with Severe COVID-19: A Single Centre Experience

ACTA MEDICA INDONESIANA · Vol. 54 No. 3 (2022)

ISSN
2338-2732, 0125-9326
Terbit
2022-09-24
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Mortality rate among maintenance hemodialysis (HD) patients with COVID-19 is alarmingly high. In Fatmawati General Hospital, most of HD patients with COVID-19 presented with acute respiratory distress syndrome (ARDS). Hemoperfusion (HP) is a blood purification therapy used to remove cytokines and inflammatory mediators to prevent ARDS worsening and organ failure. We report 6 cases of COVID-19 in maintenance HD patients. HP and HD were performed in two consecutive days when patient developed early ARDS as indicated by inflammatory markers elevation. HP and HD were conducted by using resin-containing cartridge and high-flux dialyzer, respectively, for 4 hours. Improvements in CRP levels, PaO2/FiO2 ratios, and chest X-rays were observed after 2 sessions of HP in most of our patients. Based on our clinical experience, the timing of HP delivery is critical and should be undertaken in the early phase of ARDS, but larger studies are still needed.

Kata kunci

Jaringan kolaborasi para penulis

33 penulis · 192 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Edi MulyanaAfiliasi tidak diketahui6
Linda NurdewatiAfiliasi tidak diketahui6
M Ikhsan MokoagowAfiliasi tidak diketahui6
Elisabeth Yasmine WardoyoAfiliasi tidak diketahui6
Aryan Yohanes DjojoAfiliasi tidak diketahui6
Giri AdjiAfiliasi tidak diketahui6
Ifael MauletiAfiliasi tidak diketahui6
Arnold HarahapAfiliasi tidak diketahui6
Achmad FauziAfiliasi tidak diketahui2
Ari F SyamAfiliasi tidak diketahui1
Cleopas M RumendeAfiliasi tidak diketahui1
Siti SetiatiAfiliasi tidak diketahui1
Ni Made HustriniAfiliasi tidak diketahui1
Ginova NainggolanAfiliasi tidak diketahui1
Tri Juli Edi TariganUniversity of Indonesia1
Marcellus SimadibrataAfiliasi tidak diketahui1
Rabbinu Rangga PribadiAfiliasi tidak diketahui1
Virly Nanda MuzellinaAfiliasi tidak diketahui1
Raisa WibowoAfiliasi tidak diketahui1
Ahmad Fariz Malvi Zamzam ZeinAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Hemoperfusion as an Adjuvant Therapy in Maintenance Hemodialysis Patients with Severe COVID-19: A Single Centre Experience</dc:title>
	<dc:creator>Wardoyo, Elizabeth Yasmine</dc:creator>
	<dc:creator>Sari, Anggraini Permata</dc:creator>
	<dc:creator>Djojo, Aryan Y</dc:creator>
	<dc:creator>Sarwono, Johanes</dc:creator>
	<dc:creator>Mokoagow, Md Ikhsan</dc:creator>
	<dc:creator>Darnindro, Nikko</dc:creator>
	<dc:creator>Nasarudin, Jerry</dc:creator>
	<dc:creator>Epriliawati, Marina</dc:creator>
	<dc:creator>Manurung, Annela</dc:creator>
	<dc:creator>Iskandar, Martha</dc:creator>
	<dc:creator>Wibisana, Krishna Adi</dc:creator>
	<dc:creator>Widyastuti, Anak Agung Arie</dc:creator>
	<dc:creator>Mardiyah, Radhiyatam</dc:creator>
	<dc:subject xml:lang="en-US">hemoperfusion</dc:subject>
	<dc:subject xml:lang="en-US">hemodialysis</dc:subject>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">cytokines</dc:subject>
	<dc:subject xml:lang="en-US">resin</dc:subject>
	<dc:subject xml:lang="en-US">nephrology</dc:subject>
	<dc:description xml:lang="en-US">Mortality rate among maintenance hemodialysis (HD) patients with COVID-19 is alarmingly high. In Fatmawati General Hospital, most of HD patients with COVID-19 presented with acute respiratory distress syndrome (ARDS). Hemoperfusion (HP) is a blood purification therapy used to remove cytokines and inflammatory mediators to prevent ARDS worsening and organ failure. We report 6 cases of COVID-19 in maintenance HD patients. HP and HD were performed in two consecutive days when patient developed early ARDS as indicated by inflammatory markers elevation. HP and HD were conducted by using resin-containing cartridge and high-flux dialyzer, respectively, for 4 hours. Improvements in CRP levels, PaO2/FiO2 ratios, and chest X-rays were observed after 2 sessions of HP in most of our patients. Based on our clinical experience, the timing of HP delivery is critical and should be undertaken in the early phase of ARDS, but larger studies are still needed.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2022-09-24</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2039</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 54 No. 3 (2022): Acta Medica Indonesiana; 444</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2039/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2022 Elizabeth Yasmine Wardoyo</dc:rights>
</oai_dc:dc>